Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Syndax Pharmaceuticals Inc.
Sponsor

Syndax Pharmaceuticals Inc.

United States 35 Gatehouse Drive, 02451-1215, United States

About the sponsor

Clinical research in acute myeloid leukemia, including newly diagnosed AML with NPM1 mutation and relapsed or refractory acute leukemias, with attention to disease control, remission outcomes, and treatment response in genetically defined subgroups.

  • Acute Myeloid Leukemia
  • Relapsed/Refractory Leukemias
  • NPM1-mutated AML
  • KMT2A/MLL
  • NUP98

Interest extends to measurable residual disease clearance, complete remission, and event-free survival in combination with intensive chemotherapy.

About Specializations

Syndax Pharmaceuticals Inc. runs clinical trials in conditions such as Acute myeloid leukaemia, Acute leukaemia, Chronic graft versus host disease, Idiopathic pulmonary fibrosis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Acute myeloid leukaemia

Recruiting

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

Acute leukaemia

Recruiting

Study on the Safety and Tolerability of SNDX-5613 for Patients with Relapsed or Refractory Acute Leukemias

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Revumenib
  • Sponsor:Syndax Pharmaceuticals Inc.

Chronic graft versus host disease

Not recruiting

Study of Axatilimab for Patients with Chronic Graft Versus Host Disease After Two Prior Treatments

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Idiopathic pulmonary fibrosis

Not recruiting

Study on Axatilimab for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.